I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site

Idiopathic Pulmonary Fibrosis

What's new

Sign up or login to unlock the full suite of MEDICALLY features

Oct 12 / Roche and Genentech
Race-Specific Reference Values Impede Access to Care for Black and Hispanic Patients with Pulmonary Fibrosis
An analysis of data from the Pulmonary Fibrosis Foundation Patient Registry to evaluate how using race-specific and race-neutral approaches to measuring pulmonary function can impact access to care for patients with pulmonary fibrosis from different race/ethnic backgrounds.

Sign up or login to unlock the full suite of MEDICALLY features

Independent content
Sep 25 / Springer Healthcare
European Respiratory Society (ERS) 2023: In-depth report
This in-depth report provides an overview of the latest advances in the diagnosis, treatment and management of chronic obstructive pulmonary disease and interstitial lung disease presented at ERS 2023.

Sign up or login to unlock the full suite of MEDICALLY features

Aug 28 / Roche and Genentech
Autoantibody Positivity in Idiopathic Pulmonary Fibrosis: Outcomes From the Pulmonary Fibrosis Foundation Patient Registry
This poster describes the baseline characteristics and clinical outcomes in patients with IPF from the Pulmonary Fibrosis Foundation Patient Registry (PFF-PR), stratified by baseline AAb status.

Sign up or login to unlock the full suite of MEDICALLY features

May 21 / Roche and Genentech
Factors Associated With Persistence With Antifi brotic Therapy in Patients With Idiopathic Pulmonary Fibrosis Enrolled in the Pulmonary Fibrosis Foundation Patient Registry
PFF – This poster reports an analysis that aimed to investigate the demographic and clinical characteristics associated with antifibrotic therapy persistence among patients with IPF from the Pulmonary Fibrosis Foundation Patient Registry.

Sign up or login to unlock the full suite of MEDICALLY features

May 21 / Roche and Genentech
External Validation and Longitudinal Application of a Multidimensional Index to Individualize Survival Prediction in Idiopathic Pulmonary Fibrosis
DO-GAP - This poster reports an analysis that aimed to externally validate the DO-GAP index using clinical trial data from the CAPACITY studies.

Sign up or login to unlock the full suite of MEDICALLY features

Oct 17 / Roche and Genentech
Post-hoc analysis of clinical characteristics and outcomes in patients with idiopathic pulmonary fibrosis (IPF) by pulmonary vascular phenotype from CAPACITY
This post-hoc analysis aimed to determine if the mPAP calculator can be used to identify patients with less physiologically impaired IPF at risk of worse outcomes due to PH by comparing data from placebo-treated patients with probable PH vs those with unlikely PH from CAPACITY (NCT00287729; NCT00287716).
Upcoming congresses
Access to Roche and Genentech’s latest medical information
View related congresses

Ask a question or share feedback